We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600745:SSEWingtech Technology Co., Ltd. Class A Analysis

Data as of 2026-05-29 - not real-time

CN¥20.67

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Wingtech Technology’s price of CNY 20.67 sits well below its discounted cash‑flow fair value of CNY 32.99, indicating a substantial upside potential if earnings can turn positive. The stock trades at a forward P/E of 11.36 versus an industry average of 40.95, reinforcing the perception of relative cheapness. However, the firm is posting a widening net loss (trailing EPS ‑7.39) and a steep profit margin of ‑48.5%, which together flag serious earnings weakness. Technical signals are mixed: a bullish MACD histogram (+0.48) and a sub‑50 RSI (43.4) suggest short‑term buying pressure, yet the computed trend direction is bearish and 30‑day volatility is extreme at 64%, with a historic max drawdown of ‑67.6%. The balance sheet is highly leveraged (debt‑to‑equity 36.1) and beta is negative (‑0.19), exposing the equity to amplified market swings. Volume is on an upward trend, but the combination of high leverage, negative operating margins, and a recent Nexperia dispute that expanded the 2025 loss deepens the downside risk. Consequently, while valuation metrics point to undervaluation, the fundamental and risk profile compel caution.
The sector—Chinese communication‑equipment technology—carries medium to high regulatory and geographic risk due to tightening export controls and domestic policy shifts. Currency exposure is moderate, given the stock is denominated in CNY and the company’s revenue is largely domestic, but any RMB volatility could affect earnings. Liquidity appears adequate, reflected by rising volume and a market cap of CNY 25.7 bn, yet the extreme price swings and drawdown place the liquidity risk at a medium level.
Overall, the stock presents a classic value‑play paradox: attractive pricing relative to intrinsic estimates but burdened by weak profitability, high leverage, and pronounced market volatility, which together shape a cautious investment stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • bearish overall trend direction
  • high 30‑day volatility (64%)
  • negative beta amplifying market moves

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • persistent net loss and negative profit margin
  • elevated debt‑to‑equity (36.1) stressing balance sheet
  • ongoing Nexperia dispute impacting earnings outlook

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • significant valuation gap versus DCF fair value
  • forward P/E well below industry average
  • potential earnings recovery if dispute resolves

Key Metrics & Analysis

Financial Health

Revenue Growth-93.80%
Profit Margin-48.49%
P/E Ratio11.4
ROE-30.77%
ROA1.34%
Debt/Equity36.09
P/B Ratio1.0
Op. Cash FlowCN¥3.8B
Free Cash FlowCN¥3.4B
Industry P/E40.9

Technical Analysis

TrendBearish
RSI43.4
SupportCN¥15.20
ResistanceCN¥28.27
MA 20CN¥20.68
MA 50CN¥26.94
MA 200CN¥36.47
MACDBullish
VolumeIncreasing
Fear & Greed Index93.14

Valuation

Fair ValueCN¥33.00
GradeUndervalued
TypeValue

Risk Assessment

Beta-0.19
Volatility64.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.